Medexus Pharmaceuticals (TSX:MDP) Cash per Share: C$0.28 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:MDP Medexus Pharmaceuticals Inc TSX:MDP
52 GF Score
Price C$5.02
GF Value C$1.87
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medexus Pharmaceuticals Cash per Share?

Medexus Pharmaceuticals TSX:MDP +2.87% 52 Cash per Share is C$0.28 as of Mar. 2026. GuruFocus rates TSX:MDP with a GF Score™ of 52/100 and a GF Value™ of C$1.87 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Medexus Pharmaceuticals's Cash per Share for the quarter that ended in Mar. 2026 was C$0.28.

Medexus Pharmaceuticals  (TSX:MDP) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Medexus Pharmaceuticals Cash per Share Related Terms

Medexus Pharmaceuticals Cash per Share Historical Data

* Premium members only.

The historical data trend for Medexus Pharmaceuticals's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals Cash per Share Chart

Medexus Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.89 0.29 1.07 0.28

Medexus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 0.40 0.40 0.64 0.28
TSX:MDP
52GF Score
Medexus Pharmaceuticals Inc TSX:MDP
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medexus Pharmaceuticals Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Medexus Pharmaceuticals's Cash per Share for the fiscal year that ended in Mar. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=8.95/32.0
=0.28

Medexus Pharmaceuticals's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=8.95/32.0
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of C$0.28 mean?
Medexus Pharmaceuticals (TSX:MDP) has a Cash per Share of C$0.28 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Medexus Pharmaceuticals and its competitors.
Is Medexus Pharmaceuticals' Cash per Share too high?
Medexus Pharmaceuticals' current Cash per Share is C$0.28. Overall, Medexus Pharmaceuticals has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Cash per Share compare to ZTS?
Medexus Pharmaceuticals' Cash per Share of C$0.28 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Drug Manufacturers company?
A good Cash per Share depends on the Drug Manufacturers industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Medexus Pharmaceuticals and its competitors. Medexus Pharmaceuticals's current Cash per Share is C$0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (TSX:MDP) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.87, compared to a current price of C$5.02 — trading 168.4% above its estimated fair value. The current Cash per Share is C$0.28. Medexus Pharmaceuticals' overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Medexus Pharmaceuticals (TSX:MDP), the current Cash per Share is C$0.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medexus Pharmaceuticals (TSX:MDP) Overvalued in 2026?

Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued. The current stock price of C$5.02 is trading 168.4% above its estimated GF Value™ of C$1.87. GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for TSX:MDP:

  • Cash per Share: C$0.28
  • GF Value™: C$1.87 vs. price of C$5.02 (168.4% above fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the TSX:MDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medexus Pharmaceuticals Business Description

Other Exchanges MEDXF:USAP731:Germany
Address 10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
52GF Score

Get the complete analysis for TSX:MDP

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$5.02
Price
C$1.87
GF Value